Navigation Links
Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars
Date:10/14/2010

CHAPEL HILL Two years ago, a study by University of North Carolina at Chapel Hill researchers found that an anti-vomiting drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.

Now a new economic analysis led by Canadian researchers, in collaboration with Michael J. Steiner, MD, assistant professor of pediatrics at UNC, concludes that routinely giving ondansetron to children with gastroenteritis-induced vomiting would prevent thousands of hospitalizations and save millions of dollars each year.

"In the past, people always thought that ondansetron was so expensive that its use 'wasn't worth it.' Our findings challenge that belief and may change clinician decision-making as well as practice guidelines," Steiner said.

The new study was published online this week by the journal PLoS Medicine. The lead author is Stephen B. Freedman, MDCM, a pediatric emergency physician at The Hospital for Sick Children (SickKids) and assistant professor of pediatrics at the University of Toronto. Co-authors are Steiner and Kevin J. Chan, MD, also a pediatric emergency physician at SickKids.

"This study is the first to demonstrate that in addition to being clinically beneficial, the administration of oral ondansetron to children with dehydration and persistent vomiting secondary to gastroenteritis, is economically advantageous, making it a dominant treatment strategy," Freedman said.

Gastroenteritis is an infection, often caused by a virus, that causes vomiting and diarrhea. It is popularly called "stomach flu" and is a very common ailment in children during the winter months. Persistent vomiting from acute gastroenteritis can be very frightening to children and their families and also poses a risk of dehydration.

In many cases gastroenteritis in children can be managed effectively with oral fluids, including oral rehydration therapy, but some cases are severe enough to require hospital admission for intravenous fluids. However, current practice guidelines do not recommend the use of ondansetron, in part because there was a lack of clear evidence that the treatment is cost effective.

To answer this question, study authors used a type of statistical analysis, called decision tree analysis, to compare the costs of treatment in the hospital emergency department setting both with and without ondansetron. Due to significant price differences between the U.S. and Canada, they conducted a separate analysis for each country.

They concluded that giving ondansetron to eligible children in the U.S. would prevent 29,246 intravenous insertions and 7,220 hospitalizations each year, with annual savings of $65.6 million to society and $61.1 million to payers of health care costs (including private insurance providers and Medicare and Medicaid). In Canada, the study concluded, ondansetron given routinely would prevent 4,065 intravenous insertions and 1,003 hospitalizations each year, with annual savings of $1.72 million (in Canadian dollars) to society and $1.18 million to payers of health care costs.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Six Other E. colis Could Be Lurking In Your Valentine Days Dinner
3. Tiny fruit fly could offer big clues in fight against obesity, researcher says
4. New Book Reveals How Qigong Could Be The Eastern Answer To Botox
5. Chocolate lovers could be lowering their risk of stroke: Study
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
9. Most maternal deaths in sub-Saharan Africa could be avoided
10. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
11. New Technology Could Widen Reach of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... San Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 1st, 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This ... panel discussion will be led by clinical trial experts from the pharmaceutical company Hallux, ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are ... Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients throughout ... accelerates with the implementation of MACRA, we believe that continuing to add professionals ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... The Georgia ... Award of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes ... city of Atlanta’s built environment, the preservation of its physical heritage and the balance ...
(Date:5/25/2016)... ... 2016 , ... Serenity Recovery, a holistic treatment center for ... the many supplemental program options offered at their rehabilitation facility, this time focusing ... Belt in the Shorin-ryu style of Karate that originated in Okinawa, Japan, and ...
(Date:5/25/2016)... ... ... to an article published May 5th on The Daily Mail, a survey pointed ... it found that more than a third cited unappealing breath a one of their top ... a failure to brush after meals, can typically be attributed to gum disease. Moreover, the ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology: